1. Stern DF. Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Res 2000;2:176–83.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177–82.
3. Press MF, Slamon DJ, Flom KJ, Park J, et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002;20:3095–105.
4. Smith I, Procter M, Gelber RD, Guillaume S, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29–36.
5. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719–26.
6. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–92.
7. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639–48.
8. Molina MA, Sáez R, Ramsey EE, Garcia-Barchino MJ, et al. NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res 2002;8:347–53.
9. Scaltriti M, Rojo F, Ocaña A, Anido J, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007;99:628–38.
10. Bence AK, Anderson EB, Halepota MA, Doukas MA, et al. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest New Drugs 2005;23:39–49.
11. Herendeen JM, Smith DA, Stead A, Bowen C, et al. An open-label, fixed sequence, two period study to evaluate the potential induction of GW572016 metabolism by carbamazepine. J Clin Oncol 2004;22:3081.
12. Smith DA, Bowen C, Herendeen JM, Stead A, et al. An open-label, randomized, two-way crossover study to evaluate the potential inhibition of GW572016 metabolism by ketoconazole. J Clin Oncol 2004;22:3071.
13. Geyer CE, Forster J, Lindquist D, Chan S, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733–43.
14. Cameron D, Casey M, Press M, Lindquist D, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008 Jan 11. [Epub ahead of print]
15. Lin NU, Dieras V, Paul D, Lossignol D, et al. EGF105084 Study Group. EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). J Clin Oncol 2007;25:1012.
16. Fachinformation Tyverb®, Stand Juni 2008.
Prof. Dr. med. Clemens Unger, Klinik für Tumorbiologie, Breisacher Straße 117, 79106 Freiburg, E-Mail: email@example.com
Dr. rer. nat. Annemarie Musch, Redaktion Arzneimitteltherapie, Birkenwaldstraße 44, 70191 Stuttgart